{"id":"nvx-cov2373-nvx-cov2515","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NVX-CoV2373 is a recombinant nanoparticle vaccine expressing the spike protein of the original SARS-CoV-2 strain, while NVX-CoV2515 expresses the spike protein of the Omicron variant. Together, this bivalent formulation aims to broaden immune coverage against multiple circulating variants of concern, enhancing both antibody and T-cell responses to reduce infection and severe disease risk.","oneSentence":"A bivalent recombinant protein vaccine that stimulates immune responses against both the original SARS-CoV-2 strain and the Omicron variant to prevent COVID-19.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:43.496Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT05372588","phase":"PHASE3","title":"Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2022-05-25","conditions":"COVID-19, SARS CoV 2 Infection","enrollment":1340}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prototype/BA.1 Bivalent Vaccine"],"phase":"phase_3","status":"active","brandName":"NVX-CoV2373 + NVX-CoV2515","genericName":"NVX-CoV2373 + NVX-CoV2515","companyName":"Novavax","companyId":"novavax","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A bivalent recombinant protein vaccine that stimulates immune responses against both the original SARS-CoV-2 strain and the Omicron variant to prevent COVID-19. Used for COVID-19 prevention in adults (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}